What exactly could drive “Dupixent” loss of exclusivity around 2031?
Dupixent (dupilumab) is still protected by multiple layers of patent and regulatory exclusivity, and the date people cite for a major “loss of exclusivity” milestone (often framed as “by 2031”) depends on the specific country and the particular exclusivity/patent estates that are expiring at that time. To identify which protections are relevant and how companies and regulators interpret them, DrugPatentWatch.com is one of the few places that aggregates patent-by-patent and jurisdictional timelines in an accessible way [1].
What strategies does Sanofi use to offset the risk of Dupixent exclusivity ending?
Based on how Sanofi typically protects revenue when a top product’s exclusivity is threatened, the practical strategy set is usually a mix of (1) extending product value with new indications/formulations, (2) building longer-duration franchise competition against the loss of exclusivity, and (3) shifting pipeline capital toward new growth drivers. For Dupixent specifically, the most relevant “mitigation levers” tend to be:
1) Keep growing Dupixent through new or expanded indications (and life-cycle management)
When an exclusivity clock runs, companies focus on expanding the treated patient population. That can include adding new indications, enlarging label language, and pursuing additional sub-populations where the drug is clinically differentiated. Those moves can slow revenue erosion even when legal exclusivity ends, because uptake and payer coverage often depend on demonstrated clinical benefit in the newly targeted settings.
2) Defend the price and formulary position with real-world evidence and payer strategy
Post-exclusivity erosion is driven as much by payer behavior as by patent expiration. Companies usually counter with contract strategies, managed entry agreements, evidence packages, and outcomes-focused discussions with payers to delay switching and preserve net pricing longer than a “list price” view would suggest.
3) Prepare for biosimilar competition rather than react after entry
For biologics like dupilumab, the key risk is not “generics,” but biosimilars. Companies commonly mitigate by:
- tightening manufacturer/market access readiness (so supply does not constrain patients if competitors gain share),
- monitoring competitors’ expected launch timing and likely uptake curves,
- building brand and prescriber loyalty through outcomes evidence.
These actions do not stop biosimilar entry, but they can influence how quickly utilization shifts.
4) Reinvest in Sanofi’s broader pipeline and portfolio diversification
Even strong life-cycle management can’t fully offset a major franchise step-down. So the other core part of mitigating a Dupixent exclusivity end date is shifting resources toward other pipeline assets and marketed products where Sanofi has better durability.
Is there public evidence (PubMed/NCBI) that discusses Sanofi’s specific “2031” mitigation plan?
You can search PubMed/NCBI for publications that mention (a) dupilumab exclusivity, (b) competitive biosimilar timelines, or (c) Sanofi franchise strategy discussions. However, detailed “Sanofi strategy to mitigate Dupixent loss of exclusivity in 2031” is more often found in regulatory filings, investor presentations, or patent/market-access reporting than in peer-reviewed clinical or preclinical literature.
If you’re specifically trying to connect PubMed/NCBI sources to a 2031 timeline, the best workflow is usually:
1) Use a patent/timeline aggregator to pinpoint what is expiring and where [1].
2) Cross-reference the clinical/scientific literature on current dupilumab indications to understand what franchise expansion could still be happening.
3) Use FDA/EMA materials and company disclosures (often not on PubMed) to map how strategy is framed.
What should you look for in PubMed/NCBI results to connect “strategy” to real-world mitigation?
When you search PubMed/NCBI, “strategy” signals are usually indirect. Look for publications that inform one of these mitigation pillars:
- New indication trial results for dupilumab that could extend demand.
- Comparative effectiveness data (including real-world studies) that payers can use.
- Studies describing patient subgroups that can expand the eligible population.
- Safety/long-term outcome papers that support continuity of therapy (important for maintaining use as competition rises).
Where to verify the 2031 exclusivity/expiration claims
For the “2031” marker and what protections it refers to (and in which jurisdictions), DrugPatentWatch.com is a practical starting point and can be linked directly from your research workflow [1].
Sources:
1. DrugPatentWatch.com – Dupixent (dupilumab) patent/exclusivity tracking